Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

117.17 -0.42 (-0.36%)

Streaming Delayed Price Updated: 12:38 PM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Small-Cap Stocks Skating on Thin Ice

March 06, 2025

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...

Via StockStory

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth ↗

March 04, 2025

Repligen acquires 908 Devices' desktop portfolio for $70 million, enhancing its bioprocessing analytics. 908 Devices shifts focus to handheld growth, forecasting revenue gains.

Via Benzinga

The Analyst Verdict: Repligen In The Eyes Of 4 Experts ↗

February 21, 2025

Via Benzinga

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook ↗

February 20, 2025

Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers.

Via Benzinga

Repligen's Q4 Slightly Tops Expectations ↗

February 20, 2025

The bioprocessing technology specialist's fourth-quarter results were dragged down by restructuring costs.

Via The Motley Fool

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Evaluating Repligen: Insights From 6 Financial Analysts ↗

September 26, 2024

Via Benzinga

These Analysts Revise Their Forecasts On Repligen Following Q2 Results ↗

July 31, 2024

Via Benzinga

Repligen Corp. (NASDAQ: RGEN) Making Surprising Moves in Tuesday Session

April 23, 2024

Via Investor Brand Network

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

February 20, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $167.5 million. The company’s outlook for the...

Via StockStory

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

February 19, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know.

Via StockStory

3 Healthcare Stocks Skating on Thin Ice

February 12, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But near-term speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and...

Via StockStory

Topics Stocks

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth ↗

November 12, 2024

Repligen Q3 earnings beat expectations with $0.43 EPS and $154.87 million in sales. The company raises 2024 EPS guidance and reports strong growth in CDMO and equipment.

Via Benzinga

Topics Earnings

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 12, 2024

Via Benzinga

Wall Street Ticks Up As Consumer Sentiment Improves; Gold Hits Record Highs, Boosting Mining Stocks: What's Driving Markets Friday? ↗

August 16, 2024

Wall Street edged slightly higher on Friday, with major equity indices showing modest gains at midday in New York.

Via Benzinga

Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio? ↗

August 04, 2024

Seven mid-cap stocks that performed well last week: LUMN, SHAK, PSN, CWAN, RGEN, FTDR, and NEO. Check if they're in your portfolio!

Via Benzinga

Here's Why Shares in This Hot Healthcare Stock Surged This Week ↗

August 02, 2024

The bioprocessing market is preparing for a recovery.

Via The Motley Fool

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 30, 2024

Via Benzinga

Repligen Lowers Guidance On China Weakness, Analyst Expects ↗

July 30, 2024

Repligen reports Q2 sales of $154.1 million, closely matching the consensus estimate. Adjusted gross margin fell to 49.6% from 50.2%, with an EPS of $0.33. CEO Tony J. Hunt highlights strong Pharma...

Via Benzinga

PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday ↗

July 30, 2024

Via Benzinga

This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

June 26, 2024

Via Benzinga

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

June 26, 2024

Via Benzinga

Top 3 Health Care Stocks That Could Blast Off In June ↗

June 21, 2024

Via Benzinga

Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 13, 2024

Via Benzinga

RGEN Stock Earnings: Repligen Misses EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

RGEN stock results show that Repligen missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday ↗

April 23, 2024

Via Benzinga

Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday ↗

March 25, 2024

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.

Via Benzinga

Topics Stocks

What's Going On With Life Science-Focused Repligen Stock Today? ↗

February 21, 2024

Repligen posts Q4 2023 results. CEO Tony Hunt highlights order strength in Filtration and Analytics. Positive momentum in new modalities; 2024 revenue forecast: $620-$650 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.